Skip to content

The Value of Urine Composition in the Diagnosis of Prostate Diseases

The Value of Urine Composition in the Diagnosis of Prostate Diseases

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400087462
Enrollment
Unknown
Registered
2024-07-29
Start date
2024-07-31
Completion date
Unknown
Last updated
2024-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate lesions (including but not limited to prostate cancer, prostatitis, benign prostatic hyperplasia)

Interventions

Disease group:No intervention

Sponsors

Shanghai Sixth People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1) History of transurethral or transrectal surgery/treatment within 2 weeks 2) Accompanied by acute urinary system infection 3) Previously underwent prostate surgery or interventional treatment 4) Not meeting the diagnostic criteria for prostate diseases such as benign prostatic hyperplasia, chronic prostatitis (type II, type IIIA, or type IIIB), or prostate cancer (disease group), or unable to rule out prostate diseases such as benign prostatic hyperplasia, chronic prostatitis, or prostate cancer through previous examinations (health group) 5) No history of tumors in other parts of the urinary system

Exclusion criteria

Exclusion criteria: 1) Violation of selection criteria and incorrect inclusion; 2) Patients in the disease group were lost to follow-up within 3 months after treatment.

Design outcomes

Primary

MeasureTime frame
Inflammatory factors;Urine extracellular vesicles;Urine cells;

Secondary

MeasureTime frame
Imaging examination(ultrasound, CT, MRI, etc.);Urine sediment;

Countries

China

Contacts

Public ContactLujie Song

Shanghai Sixth People’s Hospital

ljsong@sjtu.edu.cn+86 189 3017 2157

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026